EPB41L4A-AS1: A Potential Drug Target and Biomarker (G114915)

Target Name: EPB41L4A-AS1

NCBI ID: G114915

EPB41L4A-AS1

Other Name(s): EPB41L4A antisense RNA 1 | C5orf26 | NCRNA00219 | TIGA1

EPB41L4A-AS1: A Potential Drug Target and Biomarker

Epigenetic regulation plays a crucial role in the development and progression of various diseases, including cancer. Epigenetic dysregulation is characterized by the modification of gene expression levels, which can result in the activation of oncogenes and the inhibition of tumor suppressor genes. One of the key epigenetic modifiers is RNA interference (RNAi), which is a post-transcriptional modification that can alter gene expression levels by skipping exon sequences or cleavage of RNA.

EPB41L4A-AS1 is an antisense RNA (ASRNA) that targets the gene encoding the protein B-cell lymphoma 1 (Bcl2), which is a well-known tumor suppressor gene that plays a critical role in the development and progression of B-cell lymphomas. The Bcl2 gene has been implicated in various diseases, including cancer, and is often overexpressed or hypermethylated, leading to its expression levels being reduced.

EPB41L4A-AS1 has been shown to induce RNAi-mediated gene expression inhibition of Bcl2 in various cell types, including cancer cells. This led to the hypothesis that EPB41L4A-AS1 may be a potential drug target or biomarker for B-cell lymphomas.

Drug Target Potential

EPB41L4A-AS1 has been shown to inhibit the expression of Bcl2 in various cell types, including cancer cells, which suggests that it may be a potential drug target for B-cell lymphomas. B-cell lymphomas are a type of cancer that originates from the immune system, and they are characterized by the production of large B cells that recognize and respond to foreign antigens.

EPB41L4A-AS1 has been shown to induce RNAi-mediated gene expression inhibition of Bcl2 in various cell types, including cancer cells. This suggests that it may be able to inhibit the expression of Bcl2 in B-cell lymphoma cells, leading to the potential for a drug that can be used to treat these cancers.

Biomarker Potential

EPB41L4A-AS1 has also been shown to be expressed in various tissues and cell types, including lymphocytes, which suggests that it may be a potential biomarker for B-cell lymphomas. The expression of EPB41L4A-AS1 may be a useful biomarker for the diagnosis and prognosis of B-cell lymphomas, as well as for evaluating the effectiveness of potential therapies.

Conclusion

In conclusion, EPB41L4A-AS1 is an antisense RNA that targets the Bcl2 gene, which is a well-known tumor suppressor gene that is often overexpressed or hypermethylated in various diseases, including cancer. The expression of EPB41L4A-AS1 has been shown to induce RNAi-mediated gene expression inhibition of Bcl2 in various cell types, including cancer cells. This suggests that EPB41L4A-AS1 may be a potential drug target or biomarker for B-cell lymphomas. Further studies are needed to confirm these findings and to develop a better understanding of the potential mechanisms of EPB41L4A-AS1.

Protein Name: EPB41L4A Antisense RNA 1

The "EPB41L4A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPB41L4A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets